IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	**10/609,298**	Confirmation No.:	**9201**
Applicant:	**Sommadossi *et al.***		
Filed:	**June 27, 2003**		
TC/A.AU.:	**1623**		
Examiner:	**Unassigned**		
Docket No.:	**06171.105059 IDX 1017**		
Customer No.:	**20786**		
Title:	**2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections**		

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR § § 1.56, 1.97 and 1.98, Applicants in the present application cite the publications listed on the accompanying PTO-1449. Additionally, Applicants enclose a copy of the International Search Report corresponding to PCT/IB03/03901 as well as copies of the cited references. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to USPTO Deposit Account No. **11-0980**.

Respectfully submitted,

Susanne Hollinger
Reg. No. 51,811

King & Spalding, LLP
191 Peachtree Street, N.E.
Atlanta, GA 30303
Office: (404)572-4600
Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 14, 2004.

Susanne Hollinger

Please type a plus sign (+) inside this box → ⊞

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3

Complete if Known	
Application Number	10/609,298
Filing Date	June 27, 2003
First Named Inventor	Sommadossi *et al.*
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105059 IDX 1017

3405771_1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pp., Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T[6]

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	Foreign Patent Document Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pp., Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T[6]
	AA	EP	0 747 389		Taiho Pharmaceutical Co.	12-11-1996		
	AB	GB	1 163 102		MERCK & Co.	09-04-1969		
	AC	GB	1 163 103		MERCK & Co.	09-04-1969		
	AD	GB	1 209 654		MERCK & Co.	10-21-1970		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published.	T[6]
	AE	**AWANO, H. *et al*,** *"Synthesis and Antiviral Activity of 5-Substitute (2'S)-2'-C-Methylcytidines and –Uridines[11]"* Nucleosides and Nucleoties, Part 144 ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, Vol. 329, 01 February 1996 (1996-02-01), pp. 66-72	
	AF	**BEIGELMAN *et al.*,** *"A General Method for Synthesis of 3'-C-Alkylnucleosides"* Nucleic Acids Symposium. Series No. 9., IRL Press, Oxford, GB, Vol. 9, no. 9, 06 September 1981 (1981-09-06), pp. 115-118	
	AG	**CAPPELLACCI, *et al.*** *"Ribose-Modified Nucleosides as Ligands for Adenosine Receptors: Synthesis, Conformational Analysis, and Biological Evaluation of 1'-C-Methyl Adenosine Analogues* Journal Of Medicinal Chemistry, American Chemical Society, 45. pp. 1196-1202	
	AH	**FARKAS, J. *et al.*,** *Nucleic Acids Components and Their Analogues. XCIV. Synthesis of 6-Amino-9(1-Deoxy-Beta-D Psicofuranosyl) P Urine*, Collection of Czechoslovak Chemical Communications, Academic Press, London GB, Vol. 32, no. 7, 1967, pp. 2663-2667	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ⊞

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	2	of	3

	Complete if Known
Application Number	10/609,298
Filing Date	June 27, 2003
First Named Inventor	Sommadossi *et al.*
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105059 IDX 1017

3405771_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published.	T[6]
	BA	**FEDEROV, I.I., *et al.,*** *"3'-C-Branched 2'-Deoxy-5-Methyluridines: Synthesis, Enzyme Inhibition, and Antiviral Properties"* Journal Of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 35, 1992, pp. 4567-4575	
	BB	**FRANCHETTI, P., *et al.,*** *"2'-C-Methyl Analogues Of Selective Adenosine Receptor Agonists: Synthesis And Binding Studies"*, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 41, 1998, pp. 1708-1715	
	BC	**HARRY-O'KURU *et al.,*** *"A Short, Flexible Route Toward 2'-C-Branched Ribonucleosides"* Journal of Org. Chemistry, American Chemical Society, Vol. 62, pp. 1754-1759	
	BD	**H. HATTORI, *et al.,*** *"Nucleosides and Nucleotides 158"* Journal of Medicinal Chemistry, American Chemical Society, Vol. 39, 1996, pp. 5005-5001	
	BE	**HREBABECKY, H. *et al.,*** *"Nucleic Acid Components and their Analogues. CXLIX. Synthesis of Pyrimidine Nucleosides Derived from 1-Deoxy-D-Psicose"*, Collection of Czechoslovak Chemical Communications, Academic Press, London, GB, Vol. 37, 1972, pp. 2059-2065	
	BF	**HREBABECKY, H. *et al.,*** *"Synthesis of 7- and 9ß-D Psicofuranosylguanine and their 1'-Deoxy Derivatives"*, Collection of Czechoslovak Chemical Communication, Academic Press, London, GB, Vol, 39, 1974, pp. 2115-2123	
	BG	**JOHNSON, *et al.,*** *"Nucleosides & Nucleotides -- 3'-C-TrufluoromethylRribonucleoside"*, , Marcel Dekker, Inc., US, Vol. 14, no. 1/2, 1995, pp. 185-194	
	BH	**LI, Nan-Sheng *et al,*** *"2'-C-Branched Ribonucleosides. 2. Synthesis of 2'-C-β-Trifluoromethyl Pyrimidine Ribonucleosides*, Organic Letters, Vol. 3, No. 7, 2001, pp. 1025-1028	
	BI	**MATSUDA , A. *et al.,*** *" Radical Deoxygenation of Tert-Alcohols in 2'-Branched-Chain Sugar Pyrimidine Nucleosides :Ssynthesis and Antileukemic Activity of 2'-Deoxy-2' (S)-Methylcytidine"* Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, Vol. 35, 1987, pp. 3967-3970	
	BJ	**MATSUDA, A. *et al.,*** *"Nucleosides and Nucleotides. 94. Radical Deoxygenation of Tert-Alcohols in 1-(2-C-alkylpentafuranosyl) Pyrimidines : Synthesis of (2'S)-2-Deoxy-2'-C-Methylcytidine, an Antileukemic Nucleoside"* Journal of Medicinal Chemistry, American Chemical Society. Washington, US, Vol. 34, 1991, pp. 234-239	
	BK	**MIKHAILOV, S. N, *et al.,*** *"Synthesis and Properties of 3'-C-Methylnucleosides and their Phosphoric esters"* Carbohydrate Research, Elsevier Scientific Publishing Company, Amsterdam, NL, Vol. 124, 1983, pp. 75-96	
	BL	**MURAL, Y. *et al,*** *"A Synthesis and an X-ray Analysis of 2'-C-, 3'-C- and 5'-C-Methylsangivamycins"* HETEROCYCLES, Vol. 33, no. 1, 1992, pp. 391-404	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ⊞

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	3	of	3

Complete if Known	
Application Number	10/609,298
Filing Date	June 27, 2003
First Named Inventor	Sommadossi *et al.*
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105059 IDX 1017

3405771_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published.	T[6]
	CA	**ONG *et al.***, *"Synthesis of 3'-C-Methyladenosine and 3'-C-Methyluridine Diphosphates and their Interaction with the Ribonucleoside Diphosphate Reductase from Corynebacterium Nephridii"* Biochemistry, American Chemical Society, Vol. 31, No. 45, 1992, pp. 11210-11215	
	CB	**ROSENTHAL, A. *et al.***, *"Branched-Chain Sugar Nucleosides. Synthesis of 3'-C-Ethyl (and 3'-C-Butyl) Uridine"* Carbohydrate Research, Elsevier Scientific Publishing Company. Amsterdam, NL, Vol. 79, 1980, pp. 235-242	
	CC	**SCHMIT, C.,** *"Synthesis of 2'-Deoxy-2'-α-Monofluoromethyl and Trifluorome Thylnucleoside"* SYNLETT, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242	
	CD	**SHARMA P.K., *et al,*** *"Synthesis of 3'-Trifluoromethyl Nucleosides as Potential Antiviral Agents"* Nucleosides, Nucleotides And Nucleic Acids, Marcel Dekker, Ann Arbor, Mi, US. Vol. 19, no. 4. 2000, pp. 757-774	
	CE	**TRONCHET *et al.***, *(72) "Synthese et desamination enzymatique des, C-hydroxymethyl-3'-et, C-methyl-3'-beta-D-xylofurannosyl-9-adenines"* Helvetica Chimica Acta, Vol. 62, 1979, pp. 689-695	
	CF	**WOLF J. *et al.***, *"New 2'-C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity, Synthesis"* Georg Thieme Verlag. Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778	

3405771_1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.